Published in Sci Transl Med on November 30, 2011
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol (2012) 2.17
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell (2016) 2.15
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med (2013) 1.76
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 1.67
Anti-IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A (2012) 1.60
Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol (2013) 1.53
Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood (2013) 1.44
Role of the PD-1 pathway in the immune response. Am J Transplant (2012) 1.35
Acute graft-versus-host disease: a bench-to-bedside update. Blood (2014) 1.23
Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res (2012) 1.17
Immune checkpoints in central nervous system autoimmunity. Immunol Rev (2012) 1.11
Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs (2012) 1.03
The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol (2014) 1.01
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. J Hematol Oncol (2017) 0.99
Staphylococcus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+) CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis. Immunology (2014) 0.95
Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med (2013) 0.94
Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. Bone Marrow Transplant (2016) 0.94
PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology (2015) 0.93
B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease. J Immunol (2014) 0.92
CD4 T Cells Mediate Both Positive and Negative Regulation of the Immune Response to HIV Infection: Complex Role of T Follicular Helper Cells and Regulatory T Cells in Pathogenesis. Front Immunol (2015) 0.90
TGF-β converts Th1 cells into Th17 cells through stimulation of Runx1 expression. Eur J Immunol (2015) 0.89
Human adipose-tissue derived mesenchymal stem cells induce functional de-novo regulatory T cells with methylated FOXP3 gene DNA. Clin Exp Immunol (2013) 0.88
Transcriptional profiling of the circulating immune response to lassa virus in an aerosol model of exposure. PLoS Negl Trop Dis (2013) 0.87
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant After PD-1 Blockade in Relapsed/Refractory Lymphoma. Blood (2017) 0.86
Viral infection of human lung macrophages increases PDL1 expression via IFNβ. PLoS One (2015) 0.86
The dynamic lives of T cells: new approaches and themes. Trends Immunol (2012) 0.85
Regulatory T cells in HIV infection: can immunotherapy regulate the regulator? Clin Dev Immunol (2012) 0.85
Immune evasion strategies used by Helicobacter pylori. World J Gastroenterol (2014) 0.85
Induction of cardiac allograft tolerance across a full MHC barrier in miniature swine by donor kidney cotransplantation. Am J Transplant (2013) 0.84
Phenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancy. PLoS One (2014) 0.84
PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res (2015) 0.84
TLR4 activation enhances the PD-L1-mediated tolerogenic capacity of colonic CD90+ stromal cells. J Immunol (2014) 0.82
Harnessing autophagy for cell fate control gene therapy. Autophagy (2013) 0.81
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther (2016) 0.81
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer Immunol Res (2014) 0.80
Immunological cells and functions in Gaucher disease. Crit Rev Oncog (2013) 0.80
Immunoevasive pericytes from human pluripotent stem cells preferentially modulate induction of allogeneic regulatory T cells. Stem Cells Transl Med (2014) 0.80
Effect of ex vivo Expanded Recipient Regulatory T Cells on Hematopoietic Chimerism and Kidney Allograft Tolerance Across MHC Barriers in Cynomolgus Macaques. Transplantation (2016) 0.80
Retinoic acid imprints a mucosal-like phenotype on dendritic cells with an increased ability to fuel HIV-1 infection. J Immunol (2015) 0.79
Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opin Biol Ther (2015) 0.79
Localization and upregulation of survivin in cancer health disparities: a clinical perspective. Biologics (2015) 0.79
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol (2015) 0.79
A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. Cancer Immunol Immunother (2013) 0.79
Heart transplantation: challenges facing the field. Cold Spring Harb Perspect Med (2014) 0.79
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. J Clin Endocrinol Metab (2016) 0.78
Mycobacteria-responsive sonic hedgehog signaling mediates programmed death-ligand 1- and prostaglandin E2-induced regulatory T cell expansion. Sci Rep (2016) 0.78
Disrupted regulatory T cell homeostasis in inflammatory bowel diseases. World J Gastroenterol (2016) 0.78
Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo. Clin Immunol (2013) 0.78
Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. Int J Clin Oncol (2016) 0.78
Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach. J Transl Med (2014) 0.77
Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells. J Leukoc Biol (2016) 0.77
Extra-thymically induced T regulatory cell subsets: the optimal target for antigen-specific immunotherapy. Immunology (2015) 0.77
Regulation of Gag- and Env-Specific CD8+ T Cell Responses in ART-Naïve HIV-Infected Patients: Potential Implications for Individualized Immunotherapy. PLoS One (2016) 0.77
Mesenchymal stromal cells: heroes or non-combatants? Cytotherapy (2013) 0.76
PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer. Sci Rep (2016) 0.76
IL-1β, But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to Mycobacterium tuberculosis. Front Immunol (2016) 0.76
PD-1 regulates KLRG1(+) group 2 innate lymphoid cells. J Exp Med (2017) 0.76
Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. Pediatr Res (2015) 0.75
Rapamycin resistant murine th9 cells have a stable in vivo phenotype and inhibit graft-versus-host reactivity. PLoS One (2013) 0.75
FOXP3-Positive Regulatory T Cells and Kidney Allograft Tolerance. Am J Kidney Dis (2016) 0.75
T-bet regulates differentiation of forkhead box protein 3+ regulatory T cells in programmed cell death-1-deficient mice. Clin Exp Immunol (2015) 0.75
Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. Oncotarget (2016) 0.75
Acquired resistance mechanisms to immunotherapy. Ann Transl Med (2016) 0.75
Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol (2016) 0.75
c-Rel in GVHD biology: a missing link. Eur J Immunol (2013) 0.75
PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology (2017) 0.75
Tbet is a critical modulator of FoxP3 expression in autoimmune graft versus host disease. Haematologica (2017) 0.75
ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control. J Exp Med (2017) 0.75
Expansion of CD25-Negative Forkhead Box P3-Positive T Cells during HIV and Mycobacterium tuberculosis Infection. Front Immunol (2017) 0.75
Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered (2016) 0.75
Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med (1989) 15.15
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity (2008) 10.26
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
Late developmental plasticity in the T helper 17 lineage. Immunity (2009) 8.81
T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells. Nat Immunol (2002) 7.28
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science (2010) 6.06
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science (2001) 5.58
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci U S A (2001) 4.76
Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest (2009) 4.74
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell (2010) 4.57
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 4.48
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res (2005) 4.42
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood (2008) 3.95
Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol (2009) 3.42
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin-12. Immunity (2009) 3.24
Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. Immunity (2010) 3.24
Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 3.21
Production of IL-10 by CD4+ T lymphocytes correlates with down-regulation of Th1 cytokine synthesis in helminth infection. J Immunol (1991) 2.70
Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 and Th1 cell functions. Immunity (2010) 2.59
PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest (2009) 2.26
Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol (2003) 2.16
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res (2010) 2.13
Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int Immunol (1994) 2.10
Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol (2006) 1.98
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95
Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity (2000) 1.92
Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther (2007) 1.91
Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood (2009) 1.80
Stimulatory effect of counterflow centrifugal elutriation in large-scale separation of peripheral blood monocytes can be reversed by storing the cells at 37 degrees C. J Clin Apher (1991) 1.61
PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J Clin Invest (2010) 1.53
Cutting edge: the Th1 response inhibits the generation of peripheral regulatory T cells. J Immunol (2009) 1.52
Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol (2010) 1.35
Interferon gamma, IL-12, IL-12R and STAT-1 immunodeficiency diseases: disorders of the interface of innate and adaptive immunity. Immunol Res (2007) 1.28
Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. Exp Hematol (2007) 1.25
Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci U S A (2004) 1.25
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs (2010) 1.22
PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages during chronic hepatitis C virus infection. Immunology (2010) 1.21
Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol (2003) 1.15
Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy (2010) 1.04
NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem Biophys Res Commun (2009) 0.98
Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. Blood (2008) 0.95
Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function. Jpn J Cancer Res (1993) 0.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 6.65
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 5.10
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol (2002) 3.43
FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci U S A (2007) 3.32
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 3.21
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology (2003) 3.20
Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol (2009) 3.06
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med (2005) 3.01
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther (2007) 2.99
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 2.90
CARs on track in the clinic. Mol Ther (2011) 2.86
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res (2009) 2.79
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med (2015) 2.77
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 2.64
Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood (2004) 2.63
Genetic therapies against HIV. Nat Biotechnol (2007) 2.50
Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity (2011) 2.49
The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med (2010) 2.40
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood (2005) 2.39
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood (2004) 2.33
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci U S A (2002) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood (2004) 2.28
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med (2012) 2.22
Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med (2003) 2.21
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection. J Virol (2003) 2.11
CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol (2003) 2.09
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 2.07
Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. Hum Pathol (2013) 2.06
Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther (2009) 1.97
Chimeric antigen receptor therapy for cancer. Annu Rev Med (2013) 1.94
Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med (2002) 1.93
Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther (2007) 1.91
Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther (2011) 1.87
CD28 costimulation is essential for human T regulatory expansion and function. J Immunol (2008) 1.86
Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood (2005) 1.84
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther (2002) 1.83
Side population keratinocytes resembling bone marrow side population stem cells are distinct from label-retaining keratinocyte stem cells. J Invest Dermatol (2003) 1.83
Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther (2004) 1.80